HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Strategies CEO Speaks To Corruption, "Entrepreneurial" Regulators

This article was originally published in The Rose Sheet

Executive Summary

Corruption in China creates a precarious competitive landscape and unusual business pressures - for foreign companies especially, according to Merrill Weingrod, CEO of consulting firm China Strategies

You may also be interested in...



Nu Skin Unfazed By Allegations Of China Violations, Projects More Growth

Following allegations from short seller Citron Research that it operates an illegal “pyramid compensation scheme” in China, Nu Skin gives investors a peek into its business model. The firm recorded sales growth of 40% in its second quarter, driven by a 152% jump in China, and “the best is yet to come,” Nu Skin says.

Council, Campaign Vie For Influence In Washington: Top Stories Of 2010

Developments in the natural/organic marketplace, FDA's pending sunscreen monograph, the regulatory fate of controversial cosmetic ingredients and the larger question of how the personal-care industry should be policed drove interest among manufacturers and stakeholders in 2010.

Council, Campaign Vie For Influence In Washington: Top Stories Of 2010

Developments in the natural/organic marketplace, FDA's pending sunscreen monograph, the regulatory fate of controversial cosmetic ingredients and the larger question of how the personal-care industry should be policed drove interest among manufacturers and stakeholders in 2010.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

RS016863

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel